Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2011 June;63(3) > Minerva Ginecologica 2011 June;63(3):305-14

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Ginecologica 2011 June;63(3):305-14

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: Italian

Selective estrogen receptor modulators: focus on bazedoxifene

Lello S.

Ginecologia Endocrinologica, Fisiopatologia della Menopausa ed Osteoporosi, Istituto Dermopatico dell’Immacolata-IRCCS Roma, Italia


PDF  


Prevention of osteopenia/osteoporosis in postmenopausal patients can reduce fracture risk. In this view, the use of Selective Estrogen Receptor Modulators (SERMs) appear to be important in managing this condition. Bazedoxifene Acetate (BZA) is a third-generation SERM that showed to protect bone mass in postmenopausal women with osteopenia, and to reduce vertebral fracture risk in osteoporotic postmenopausal women; moreover, BZA decreased the non-vertebral fracture risk in a subgroup of patients at high-risk for fracture in comparison to placebo. BZA showed no stimulating effects on endometrium and breast. BZA can be a valid option in management of osteopenia/osteoporosis in postmenopause.

top of page

Publication History

Cite this article as

Corresponding author e-mail

lellostefano@libero.it